Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma

Jonathan C. Yau, Colin Germond, Stefan Gluck, Christine Cripps, Shailendra Verma, Bruce F. Burns, Terry M. Koski, Diane C. Lister, Glenwood D. Goss

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Elderly patients with intermediate- or high-grade non-Hodgkin's lymphoma have a worse outcome than those who are younger than 60 years. It has been shown that aggressive combination chemotherapy is poorly tolerated in older patients resulting in a subsequent decrease in dose intensity. A phase II trial was conducted with mitoxantrone, prednimustine, and vincristine (NSO) in this group of patients. NSO consists of mitoxantrone 12 mg/M2 intravenously on day one, vincristine 1.4 mg/M2 intravenously on day 1 (maximum dose of two mg), and prednimustine 100 mg/M2 orally once a day for four days. NSO was repeated every 21 days. Thirty-six patients Were able to be evaluated. There were 18 males and 18 females with the median age of 71 (range 60-85). NSO was well tolerated and nonhematological toxicities were uncommon. More than 80% of the patients received 90% or greater of the intended dose. The complete response rate was 60.6% and partial response was 21.8%. At 60 months the Kaplan-Meier estimate of progression-free survival was 47.9% (standard error 8.6%) and actual survival was 40.6% (standard error 8.8%). There were no differences in outcome between those with performance status (PS) of zero or one and those with PS > 1. NSO is well tolerated by elderly patients including those with PS > 1. These results compare favorably with other combinations in elderly patients with aggressive non-Hodgkin's lymphoma.

Original languageEnglish (US)
Pages (from-to)156-160
Number of pages5
JournalAmerican Journal of Hematology
Issue number2
StatePublished - Oct 1998


  • Elderly
  • Mitoxantrone
  • Non-Hodgkin's lymphoma
  • Prednimustine
  • Vincristine

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this